TMCnet News
Anthrax Pipeline Insight 2018 Featuring Cangene Corporation & Emergent BioSolutions - ResearchAndMarkets.comThe "Anthrax - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Anthrax - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Anthrax development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages:
Descriptive coverage of pipeline development activities for Anthrax Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designatons, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Anthrax The report assesses the active Anthrax pipeline products by developmental stage, product type, molecule type, and administration route. Key Topics Covered: 1. Report Introduction 2. Anthrax Overview 3. Pipeline Therapeutics
4. Comparative Analysis 5. Products in Clinical Stage 5.1 Drug Name : Company Name
6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name
7. Therapeutic Assessment
8. Inactive Products 8.1 Drug Name : Company Name
Companies Mentioned
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lrcdlg/anthrax_pipeline?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006331/en/ |
